SCHEMBL30348557

SCHEMBL30348557

Cc1nc2ccc(-c3c[nH]c4nc(NCC5CCN(C)CC5)ncc34)cc2s1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 4/20 0.43
▸ CLK2 P49760 1/20 0.43
▸ CLK3 P49761 1/20 0.43
▸ BRD4 O60885 3/20 0.39
▸ DYRK1B Q9Y463 3/20 0.38
▸ LMNA P02545 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ DYRK2 Q92630 3/20 0.37
▸ ACP1 P24666 1/20 0.37
▸ VNN1 O95497 1/20 0.37
▸ ABL1 P00519 1/20 0.36
▸ IL2 P60568 1/20 0.36
▸ MAP4K1 Q92918 1/20 0.36
▸ MAP3K11 Q16584 1/20 0.36
▸ TNIK Q9UKE5 1/20 0.35
▸ ROCK2 O75116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25214569 1.00 DYRK1A (0.43) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL30348056 0.87 BRD4 (0.38) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL25518089 0.87 BRD4 (0.38) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL30348692 0.87 DYRK1A (0.47) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL25158417 0.87 DYRK1A (0.47) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL30406857 0.85 DYRK1A (0.49) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL25519924 0.85 DYRK1A (0.49) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL25201500 0.82 DYRK1A (0.62) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL25157442 0.82 DYRK1A (0.47) DYRK1ACLK2CLK3BRD4DYRK1B
SCHEMBL30348925 0.82 DYRK1A (0.62) DYRK1ACLK2CLK3BRD4DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback